Clinical trials: MRD
T-Cell Acute Lymphoblastic Leukemia
NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL
The purpose of this study is to determine the feasibility, safety, and efficacy of a combination therapy in the treatment of T-cell acute lymphoblastic leukemia (T-ALL): multi-antigen-targeted chimeric antigen receptor T cells…
- Trial name
- NCT05277753
- Testing
- Antigen-specific T cells CAR-T/CTL and DCvac
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Acute Myeloid Leukemia (AML)
Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML
This prospective observational study aims to evaluate the clinical significance of measurable residual disease (MRD) monitoring using digital PCR (dPCR) in patients with acute myeloid leukemia (AML) following allogeneic…
- Trial name
- NCT07500441
- Testing
- Individualized Digital PCR (dPCR) monitoring
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Tyrosine Kinase Inhibitor
Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in early first complete remission improves the long-term outcomes for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
- Conditions
- Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Tyrosine Kinase Inhibitor, Minimal Residual Disease, Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- NCT03624530
- Testing
- Tyrosine kinase inhibitor (TKIs)
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute Myeloid Leukemia, Acute Lymphoblastic T-cell Leukemia
Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation
This pilot clinical trial aims to evaluate the feasibility, adverse reactions and maximum tolerated dose of mbIL21 ex vivo-expanded donor-derived NK-cell infusions before and after haploidentical or matched-related hematopoietic…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic T-cell Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- NCT07256210
- Testing
- Donor-derived Natural Killer Cell
- Where
- Russia
- Volunteers
- 15 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
C-KIT Mutation
A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia
C-Kit is involved in an essential pathway of disease occurrence and is closely related to the poor prognosis of patients. However, the clinical significance of c-Kit mutation as molecular MRD monitoring is still unclear.
- Trial name
- NCT06116318
- Where
- China
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
B Cell Precursor Acute Lymphoblastic Leukemia
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
The Phase I part of the study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL), to…
- Trial name
- NCT04521231
- Testing
- Blinatumomab
- Where
- 109 sites in United States, Argentina and 18 more
- Volunteers
- 181 people
- Sponsor
- Amgen
Pediatric ALL, B Cell, Minimal Residual Disease
Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)
This is a single-arm, open-label, multi-center phase I study using blinatumomab for pediatric B-cell acute lymphoblastic leukemia patients with positive of minimal residual disease.
- Trial name
- NCT04604691
- Testing
- Blinatumomab for Injection
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Seoul National University Hospital
Ptosis, Eyelid
Evaluation of Intraoperative Lagophthalmos Formula
This is a prospective non-randomized study to evaluate the recent intraoperative lagophthalmos formula method for levator resection in determining postoperative eyelid height in congenital ptosis on Egyptian children.
- Trial name
- NCT04291625
- Testing
- Levator muscle resection
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Menoufia University
Pediatric Acute Lymphoblastic Leukemia
Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia
Clinical and genetic factors consistent with High risk : Induction → Consolidation 1. BM MRD \< 0.01% : IM #1 → DI #1 → IM #2 → Maintenance 2. BM MRD ≥ 0.01% : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance 3.
- Trial name
- HR ALL (NCT06184009)
- Testing
- ALL, High risk
- Where
- 9 sites in South Korea
- Volunteers
- 370 people
- Sponsor
- Jae Wook Lee
Leukemia
Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)
This is a 2 part study. The goal of the first part of this clinical research study is to find the highest tolerable dose of azacitidine that can be given with a TKI that you are already taking (such as Gleevec, Sprycel, or…
- Trial name
- NCT01460498
- Testing
- Azacitidine (AZA), Tyrosine kinase inhibitor (TKI), Azacitidine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Graft Versus Host Disease
T&B Depletion Non Malignant
The primary aim of the present trial is to assess in a randomized fashion the benefit on standard graft-versus-host disease (GVHD) prophylaxis of the addition of ATG-Fresenius S ® in transplants from matched related donors (MRD)…
- Trial name
- NCT01810926
- Testing
- polyclonal antibody, Rituximab, Treosulfan
- Where
- 4 sites in Italy
- Volunteers
- 130 people
- Sponsor
- Franco Locatelli
CD7+ T-ALL/LBL
To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT
To observe the efficacy and safety of CD7-targeted chimeric antigen receptor T cells in the treatment of T-lymphoblastic leukaemia/lymphoma with postive measurable residual disease positive post allogeneic stem cell…
- Trial name
- S101MRD (NCT07280494)
- Testing
- CAR-T Therapy
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Peking University People's Hospital
Acute Myeloid Leukemia, Childhood
A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML
Minimal-residual disease (MRD) will be measured either by flow cytometry, or polymerase chain reaction (PCR) methods, in 3 check-points and it will be one of the decision-making control parameter for the optimal therapy tactics.
- Trial name
- NCT03846362
- Testing
- HSCT
- Where
- 2 sites in Russia
- Volunteers
- 500 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
NMIBC, MIBC
A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)
This was a multicenter, prospective, non-interventional, observational cohort study, and the enrolled patients were divided into four cohorts: cohort I was patients with high-risk upper tract urothelial carcinoma (UTUC) (pT3-4 or…
- Conditions
- NMIBC, MIBC, UTUC
- Trial name
- NCT06991868
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University First Hospital
Acute Leukemia, Acute Myeloid Leukemia
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further…
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma
- Trial name
- NCT03314974
- Testing
- HSCT with TBI Regimen, HSCT with Non-TBI Regimen
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
B ALL, Allogenetic Hematopoietic Stem Cell Transplantation
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
This prospective, open-label randomized controlled trial compares CD19 CAR-T therapy with chemotherapy plus donor lymphocyte infusion (DLI) in 70 patients with Ph-negative B-cell acute lymphoblastic leukemia (B-ALL) who exhibited…
- Conditions
- B ALL, Allogenetic Hematopoietic Stem Cell Transplantation, MRD-positive
- Trial name
- NCT07441291
- Testing
- CAR-T, DLI
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking University People's Hospital
Acute Lymphoblastic Leukemia
CART-19 Cells For MRD Positive CD19+ ALL
CART-19 cells has emerged as a powerful targeted immunotherapy, showing striking responses in highly refractory CD19+ acute lymphoblastic leukemia (ALL).
- Trial name
- CCFMPCA (NCT03027739)
- Testing
- CART-19
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fujian Medical University
Acute Myeloid Leukemia
MRD Response-adapted Allo-HSCT for Adverse-risk AML
This TROPHY-AML01 regimen aims to identify the effectiveness and safety of MRD response-adapted allo-HSCT for adverse-risk acute myeloid leukemia in an open-label, randomized, controlled trial.
- Trial name
- NCT06301425
- Testing
- Intervention group, Control group
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Peking University People's Hospital
Acute Lymphoblastic Leukemia
Treatment of Adult ALL With an MRD-directed Programme.
The study aims to optimize the concept of risk-oriented postremission consolidation therapy, by offering (i) standard consolidation-maintenance to patients at lowest risk of relapse as defined by MRD(Minimal Residual Disease)…
- Trial name
- NCT00358072
- Testing
- Postremission consolidation based on MRD status
- Where
- 15 sites in Italy
- Volunteers
- 280 people
- Sponsor
- Northern Italy Leukemia Group
Multiple Myeloma
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
The purpose of this study is to determine whether giving linvoseltamab with lenalidomide during maintenance treatment to participants with multiple myeloma will: 1.
- Trial name
- NCT06910124
- Testing
- Linvoseltamab, Lenalidomide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Dickran Kazandjian, MD